News Search Results
Mar 25, 2025, 10:36 ET Hubble Therapeutics closes Series A Financing to develop gene therapy cure for LCA16
March 25, 2025 /PRNewswire/ -- Hubble Therapeutics LLC a patient-focused biotechnology company developing a gene therapy to cure pediatric blindness, announces the successful closing of a $7.3 million
More news about: Hubble Therapeutics LLC
Mar 25, 2025, 10:36 ET Hubble Therapeutics closes Series A Financing to develop gene therapy cure for LCA16
March 25, 2025 /PRNewswire/ -- Hubble Therapeutics LLC a patient-focused biotechnology company developing a gene therapy to cure pediatric blindness, announces the successful closing of a $7.3 million
More news about: Hubble Therapeutics LLC
Mar 25, 2025, 10:30 ET Drug Discovery Services Market worth US$27.23 billion in 2030 with 10.7% CAGR | MarketsandMarkets™
chemistry and structure-based drug design. In the therapeutic area, the oncology segment commanded the highest market share. Pharmaceutical and biotechnology companies are the largest end users, owing to high research & development investments. Download PDF Brochure:
More news about: MarketsandMarkets
Mar 25, 2025, 10:15 ET Caprolactam Market to Reach USD 25.77 Billion by 2031, Driven by Growing Demand in Nylon Production and Expanding Applications Across Industries: Market Research Intellect
alternatives. Traditional caprolactam production involves petrochemical feedstocks, which contribute to carbon emissions. However, advancements in biotechnology and green chemistry are enabling the production of bio-based caprolactam, reducing reliance on fossil fuels. Companies are investing in research
More news about: Market Research Intellect
Mar 25, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
March 25, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and certain officers. The class action, filed in the United States
More news about: Pomerantz LLP
Mar 25, 2025, 09:31 ET SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:
More news about: The Schall Law Firm
Mar 25, 2025, 09:15 ET WILLOW BIOSCIENCES REPORTS 2024 FINANCIAL RESULTS AND UPDATE REGARDING SALE OF OPERATING SUBSIDIARY
March 25, 2025 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a biotechnology company focused on industrial manufacturing of ingredients is pleased to announce its financial and operating results for the three months and year
More news about: Willow Biosciences Inc.
Mar 25, 2025, 09:00 ET Truist Securities strengthens its biotech equity research coverage
that Danielle Brill has joined the firm as managing director, strengthening its equity research coverage in the biotechnology sector. Brill is the latest addition to Truist Securities, as the firm continues to expand its equity platform to broaden its capabilities in high-growth
More news about: Truist Financial Corporation
Mar 25, 2025, 08:00 ET Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a letter of intent with VERDI
More news about: Anixa Biosciences, Inc.
Mar 25, 2025, 08:00 ET AngeoPro Yeast Protein Wins 2025 World Best Ingredient Innovation Award, Pioneering a New Era of Sustainable Protein
ever-growing demand for plant-based alternatives that deliver exceptional nutrition without compromising on taste or texture. Through advanced biotechnology, AngeoPro offers a complete amino acid profile, superior digestibility, and exceptional functional properties, making it ideal for applications
More news about: Angel Yeast
Mar 25, 2025, 07:30 ET Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange
More news about: Palatin Technologies, Inc.
Mar 25, 2025, 07:30 ET Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Mar 25, 2025, 07:09 ET Moa and NAICONS join forces to discover the next generation of naturally-occurring herbicides
natural product research, NAICONS collaborates with public and private institutions worldwide to drive innovation in drug discovery, agriculture and biotechnology, unlocking the potential of microbial diversity to develop next-generation solutions. Photo -
More news about: MOA Technology
Mar 25, 2025, 06:30 ET Hillstar Bio Launches with $67 Million Series A Financing to Develop Next Wave of Precision Immunotherapies to Transform Autoimmune Treatment
BOSTON, March 25, 2025 /PRNewswire/ -- Hillstar Bio, a leading biotechnology company focused on developing next-generation precision immunology therapies for autoimmune diseases, today announced the successful closing of
More news about: Hillstar Bio
Mar 25, 2025, 06:00 ET TFS HealthScience Appoints Miriam Martin as Vice President of Business Development, Clinical Development Services
TFS HealthScience is a full-service, global Contract Research Organization (CRO) that partners with biotechnology and pharmaceutical companies to advance innovative treatments and improve patient outcomes. With operations across 40 countries, TFS and its strategic
More news about: TFS HealthScience
Mar 25, 2025, 06:00 ET TFS HealthScience Appoints Miriam Martin as Vice President of Business Development, Clinical Development Services
TFS HealthScience is a full-service, global Contract Research Organization (CRO) that partners with biotechnology and pharmaceutical companies to advance innovative treatments and improve patient outcomes. With operations across 40 countries, TFS and its strategic
More news about: TFS HealthScience
Mar 24, 2025, 18:04 ET Investor Alert: Robbins LLP Informs Investors of the Sana Biotechnology, Inc. Class Action Lawsuit
persons and entities that purchased or otherwise acquired Sana Biotechnology, Inc. (NASDAQ: SANA) securities between March 17, 2023 and November 4, 2024. Sana is a biotechnology company that develops ex vivo and in vivo cell engineering
More news about: Robbins LLP
Mar 24, 2025, 17:31 ET CARVYKTI Continued Performance Reflects Growing Confidence in CAR-T Therapies for Multiple Myeloma | DelveInsight
including Bristol-Myers Squibb, I-MAB Biopharma, Pfizer, Arcellx, Gilead Sciences, Novartis, Array Biopharma, Hrain Biotechnology Co., Ltd., Cartesian Therapeutics, Xencor, Takeda, Sorrento Therapeutics, Heidelberg Pharma AG, Ichnos Sciences, Allogene Therapeutics, Harpoon
More news about: DelveInsight Business Research, LLP
Mar 24, 2025, 17:06 ET Natural Cosmetics Market Projected to Reach $35.96 Billion by 2032, Growing at 7.5% CAGR from 2025 --Exclusive Report by Meticulous Research®
adoption of biodegradable packaging solutions to minimize environmental impact. Innovation is accelerating in the sector, with companies leveraging biotechnology to develop sustainable lab-grown natural ingredients that maintain product efficacy while reducing environmental footprint. Growth Opportunities
More news about: Meticulous Market Research Pvt. Ltd.
Mar 24, 2025, 16:47 ET ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
were insufficient to shield ICON from the adverse effects of a significant market downturn; (3) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: THE ROSEN LAW FIRM, P. A.
Mar 24, 2025, 16:30 ET Nanoscope Announces Publication of Clinical Data on Vision Restoration in Retinitis Pigmentosa
Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal
More news about: Nanoscope Therapeutics
Mar 24, 2025, 15:55 ET Algal Pigments Market Projected to Reach $718 Million by 2032, Growing at 7.2% CAGR from 2025 | Meticulous Research®
Co., Ltd. (Japan)Algatechologies Ltd. (Israel)Zhejiang Binmei Biotechnology Co., Ltd (China)Algae Health Sciences (U.S.)Sochim International S.p.A. (Italy)Merck
More news about: Meticulous Market Research Private Limited
Mar 24, 2025, 14:23 ET NASA Invites Media to SpaceX's 32nd Resupply Launch to Space Station
[email protected]. Each resupply mission to the station delivers scientific investigations in the areas of biology and biotechnology, Earth and space science, physical sciences, and technology development and demonstrations. Cargo resupply from U.S. companies ensures a national
More news about: NASA
Mar 24, 2025, 11:00 ET ICLR INVESTOR ALERT: ICON PLC Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
insufficient to shield ICON from the adverse effects of a significant market downturn; (iii) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Robbins Geller Rudman & Dowd LLP
Mar 24, 2025, 10:45 ET Digestive Health Products Market Surges to USD 102.5 Billion by 2033, Propelled by 4.5% CAGR - Verified Market Reports®
gastrointestinal disorders, coupled with a shift toward preventive healthcare, is accelerating market expansion. Companies are leveraging cutting-edge biotechnology and microbiome research to develop innovative solutions, enhancing product efficacy and consumer appeal. Key challenges encompass stringent
More news about: Verified Market Reports